Seer (NASDAQ:SEER – Get Rating) is one of 42 public companies in the “Analytical instruments” industry, but how does it contrast to its peers? We will compare Seer to related businesses based on the strength of its earnings, analyst recommendations, dividends, profitability, institutional ownership, valuation and risk.
This table compares Seer and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
86.9% of Seer shares are owned by institutional investors. Comparatively, 60.8% of shares of all “Analytical instruments” companies are owned by institutional investors. 28.9% of Seer shares are owned by insiders. Comparatively, 13.4% of shares of all “Analytical instruments” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This is a summary of current recommendations and price targets for Seer and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Seer presently has a consensus target price of $21.00, indicating a potential upside of 148.52%. As a group, “Analytical instruments” companies have a potential upside of 41.82%. Given Seer’s higher probable upside, research analysts plainly believe Seer is more favorable than its peers.
Earnings & Valuation
This table compares Seer and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Seer||$6.62 million||-$71.17 million||-6.65|
|Seer Competitors||$1.16 billion||$344.59 million||-27.10|
Seer’s peers have higher revenue and earnings than Seer. Seer is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Seer has a beta of 3.13, suggesting that its stock price is 213% more volatile than the S&P 500. Comparatively, Seer’s peers have a beta of 1.21, suggesting that their average stock price is 21% more volatile than the S&P 500.
Seer peers beat Seer on 8 of the 13 factors compared.
About Seer (Get Rating)
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.